Composition for improving premature ovarian failure and preparation method thereof

Abstract

The invention belongs to the technical field of functional foods and health foods, and particularly relates to a composition for improving premature ovarian failure and a preparation method thereof. The composition comprises the following components in parts by weight: 5-15 parts of orange osmanthus pollen, 4-12 parts of flaxseed concentrated powder, 2-8 parts of black-bone chicken peptide, 4-20 parts of rehmannia powder, 2-10 parts of cistanche powder and 1-5 parts of lemon concentrated powder. The composition for improving premature ovarian failure prepared by the invention can reduce the content of follicle stimulating hormone (FSH) and luteinizing hormone (LH) in the serum of a premature ovarian failure rat induced by cyclophosphamide and increase the content of estradiol (E2), thereby achieving the effect of improving premature ovarian failure.

Description

Technical Field

[0001] The present invention belongs to the technical field of functional foods and health foods, and particularly relates to a composition for improving premature ovarian failure and a preparation method thereof. Background Art

[0002] Premature ovarian failure (POF) refers to the failure of ovarian function in women before the age of 40, characterized by elevated concentrations of serum follicle stimulating hormone (FSH) and luteinizing hormone (LH), and a decrease in the concentration of estradiol (E2). The general manifestations are primary or secondary amenorrhea, accompanied by elevated levels of gonadotropins and decreased estrogen levels, and varying degrees of low estrogen symptoms, such as hot flashes, sweating, facial flushing, low libido, etc. It can also cause a series of serious complications, such as postmenopausal osteoporosis, postmenopausal syndrome, cardiovascular diseases, obesity, and diabetes, seriously affecting the quality of life of women.

[0003] Currently, the clinical treatment methods for improving premature ovarian failure are limited. Western medicine often uses hormone replacement therapy (HRT) to relieve the symptoms brought about by ovarian aging, but long-term use will increase the risk of cancer and lead to abnormal weight fluctuations. The present invention combines natural plant ingredients and ingredients homologous to medicine and food to achieve the effect of improving premature ovarian failure. Summary of the Invention

[0004] To solve the above problems, on the one hand, the present invention provides a composition for improving premature ovarian failure. This composition is safe and effective, can reduce the contents of follicle stimulating hormone (FSH) and luteinizing hormone (LH) in the serum of rats with premature ovarian failure induced by cyclophosphamide, and increase the content of estradiol (E2), thereby achieving the effect of improving premature ovarian failure.

[0005] On the other hand, the present invention provides a preparation method of a composition for improving premature ovarian failure. This method has a simple process, is easy to operate, and is suitable for industrial production.

[0006] To achieve the above object, the technical content of the present invention is as follows:

[0007] On the one hand, the present invention provides a composition for improving premature ovarian failure, which includes 5 - 15 parts by weight of osmanthus flower pollen, 4 - 12 parts of flaxseed concentrated powder, 2 - 8 parts of black-bone chicken peptide, 4 - 20 parts of rehmannia powder, 2 - 10 parts of cistanche powder, and 1 - 5 parts of lemon concentrated powder.

[0008] Preferably, by weight, it includes 8-12 parts of osmanthus flower pollen, 7-10 parts of flaxseed concentrated powder, 3-5 parts of black-bone chicken peptide, 9-15 parts of rehmannia powder, 4-8 parts of cistanche powder, and 2-4 parts of lemon concentrated powder.

[0009] Preferably, the weight ratio of the osmanthus flower pollen to the flaxseed concentrated powder is (1-1.5):1; more preferably, the weight ratio of the osmanthus flower pollen to the flaxseed concentrated powder is (1-1.25):1; even more preferably, the weight ratio of the osmanthus flower pollen to the flaxseed concentrated powder is 1.25:1.

[0010] Preferably, the weight ratio of the total weight of the osmanthus flower pollen and the flaxseed concentrated powder to the lemon concentrated powder is (1.5-15):1; more preferably, the weight ratio of the total weight of the osmanthus flower pollen and the flaxseed concentrated powder to the lemon concentrated powder is (1.5-6):1; even more preferably, the weight ratio of the total weight of the osmanthus flower pollen and the flaxseed concentrated powder to the lemon concentrated powder is 6:1.

[0011] Preferably, the weight ratio of the total weight of the osmanthus flower pollen and the flaxseed concentrated powder to the black-bone chicken peptide is (3-8):1; more preferably, the weight ratio of the total weight of the osmanthus flower pollen and the flaxseed concentrated powder to the black-bone chicken peptide is (3-4.5):1; even more preferably, the weight ratio of the total weight of the osmanthus flower pollen and the flaxseed concentrated powder to the black-bone chicken peptide is 4.5:1.

[0012] Preferably, the weight ratio of the total weight of the osmanthus flower pollen and the flaxseed concentrated powder to the rehmannia powder is (1-3):1; more preferably, the weight ratio of the total weight of the osmanthus flower pollen and the flaxseed concentrated powder to the rehmannia powder is (1-2):1; even more preferably, the weight ratio of the total weight of the osmanthus flower pollen and the flaxseed concentrated powder to the rehmannia powder is 1.4:1.

[0013] Preferably, by weight, it includes 10 parts of osmanthus flower pollen, 8 parts of flaxseed concentrated powder, 4 parts of black-bone chicken peptide, 13 parts of rehmannia powder, 6 parts of cistanche powder, and 3 parts of lemon concentrated powder.

[0014] Preferably, the osmanthus flower pollen contains acteoside, and the acteoside content is not less than 12%.

[0015] Preferably, the flaxseed concentrated powder contains lignans, and the lignan content is not less than 40%.

[0016] Preferably, the eriocitrin content in the lemon concentrated powder is not less than 10%.

[0017] Preferably, the black-bone chicken peptide is prepared by pre-treating (cutting and grinding) black-bone chicken, steaming, enzymatic hydrolysis (neutral protease and bromelain), inactivating enzymes, filtering and removing impurities, drying, etc.

[0018] Preferably, the method for preparing the rehmannia powder is as follows: raw rehmannia and water are obtained through the steps of soaking, filtering, and concentrating, wherein the concentration ratio is 10:1.

[0019] Preferably, the method for preparing the cistanche powder is obtained by extracting and concentrating the fleshy stem with scale leaves of cistanche and water, wherein the concentration ratio is 10:1.

[0020] On the other hand, the present invention provides a method for preparing the above composition, which includes weighing osmanthus powder, flaxseed concentrated powder, black-bone chicken peptide, rehmannia powder, cistanche powder, and lemon concentrated powder, and uniformly mixing and sterilizing with ultraviolet light to obtain the composition.

[0021] Preferably, the time for uniform mixing is 20 - 40 min; more preferably, the mixing time is 30 min.

[0022] Preferably, the sterilization time is 10 - 30 min; more preferably, the sterilization time is 20 min.

[0023] On yet another aspect, the present invention provides the application of the above composition in the preparation of products for improving premature ovarian failure.

[0024] Preferably, the dosage form of the product is powder, tablet, granule, pill, or capsule.

[0025] Compared with the prior art, the present invention has the following advantages:

[0026] Osmanthus powder contains acteoside, and acteoside has antioxidant effects, which can protect cells from free radical damage and maintain the normal structure and function of cells. It can also inhibit apoptosis by reducing the expression of pro-apoptotic proteins, thereby protecting ovarian function.

[0027] Flaxseed concentrated powder contains lignans, which are a type of phytoestrogen that can bidirectionally regulate the estrogen level in the human body and show weak estrogen or anti-estrogen effects. When the human body lacks estrogen, lignans can act on estrogen receptors on cells, maintain the normal metabolism and function of ovarian cells, and reduce ovarian atrophy and functional decline caused by estrogen deficiency.

[0028] Black-bone chicken peptide is rich in various nutritional components such as amino acids and trace elements, which can provide nutrition and ensure the normal physiological functions of cells.

[0029] Rehmannia powder has the effects of nourishing yin and tonifying the kidney, enriching blood and replenishing essence, and has antioxidant ability.

[0030] Cistanche powder has the functions of tonifying kidney yang and benefiting essence and blood, has a strong estrogen effect, and maintains endocrine stability.

[0031] The lemon concentrated powder contains components such as eriocitrin and citrus flavonoids, which enhance the antioxidant capacity of the body.

[0032] 1. The composition for improving premature ovarian failure provided by the present invention adopts six raw materials: osmanthus powder, flaxseed concentrated powder, black-bone chicken peptide, rehmannia powder, cistanche powder and lemon concentrated powder. Among them, osmanthus powder and flaxseed concentrated powder are the main raw materials. On this basis, rehmannia powder is added, and black-bone chicken peptide, cistanche powder and lemon concentrated powder are supplemented. The above several homologous medicine and food raw materials act synergistically, which can reduce the contents of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) in the serum of rats with premature ovarian failure induced by cyclophosphamide, and increase the content of estradiol (E2), thereby improving premature ovarian failure.

[0033] 2. The composition for improving premature ovarian failure provided by the present invention has raw materials all derived from natural plants, and no complex processes and chemical reagents are used in the preparation process, which can retain the effective components of the raw materials to the greatest extent and ensure the quality and efficacy of the product.

[0034] 3. The preparation method of the composition for improving premature ovarian failure provided by the present invention is simple and suitable for industrial production. Specific Embodiments

[0035] The following non-limiting examples can enable those of ordinary skill in the art to understand the present invention more comprehensively, but do not limit the present invention in any way. The following content is only an exemplary illustration of the scope claimed by the present invention. Those skilled in the art can make various changes and modifications to the present invention based on the disclosed content, and it should also fall within the scope claimed by the present invention.

[0036] When the embodiments give numerical ranges, it should be understood that unless otherwise specified in the present invention, any value between the two endpoints of each numerical range and any value between the two endpoints can be selected. Unless otherwise defined, all technical and scientific terms used in the present invention have the same meaning as commonly understood by those of ordinary skill in the technical field to which the present invention belongs.

[0037] The present invention will be further described below by way of specific examples. All chemical reagents used in the embodiments of the present invention are obtained through conventional commercial channels unless otherwise specified. Products from different manufacturers have no significant impact on the effect.

[0038] Osmanthus powder: Purchased from Shanghai Haoyun Biotechnology Co., Ltd., the content of acteoside is ≥12%; Flaxseed concentrated powder: Purchased from Shanghai Haoyun Biotechnology Co., Ltd., the content of lignans is 40%; Black-bone chicken peptide: Purchased from Hubei Qimei Biotechnology Co., Ltd.; Rehmannia powder: Purchased from Nanjing Zhenweikang Biotechnology Co., Ltd.; Cistanche powder: Purchased from Nanjing Zhenweikang Biotechnology Co., Ltd.; Lemon concentrated powder: Purchased from Shanyi Food (Shanghai) Co., Ltd.

[0039] Example 1

[0040] This example provides a composition for improving premature ovarian failure, including 10 parts by weight of osmanthus flower pollen, 8 parts by weight of flaxseed concentrated powder, 4 parts by weight of black-bone chicken peptide, 13 parts by weight of rehmannia root powder, 6 parts by weight of cistanche deserticola powder, and 3 parts by weight of lemon concentrated powder.

[0041] The total weight of the composition in the example is 100 g, and its preparation method is as follows:

[0042] (1) Weigh and prepare the ingredients: Weigh various materials according to the ratio and set aside.

[0043] (2) Pour the materials weighed in step (1) into a cleaned three-dimensional mixer respectively, mix for 30 min, and sterilize with ultraviolet light for 20 min to obtain the composition.

[0044] Example 2

[0045] This example provides a composition for improving premature ovarian failure, including 5 parts by weight of osmanthus flower pollen, 4 parts by weight of flaxseed concentrated powder, 2 parts by weight of black-bone chicken peptide, 4 parts by weight of rehmannia root powder, 10 parts by weight of cistanche deserticola powder, and 5 parts by weight of lemon concentrated powder.

[0046] The total weight of the composition in the example is 100 g, and its preparation method is the same as that of Example 1.

[0047] Example 3

[0048] This example provides a composition for improving premature ovarian failure, including 8 parts by weight of osmanthus flower pollen, 7 parts by weight of flaxseed concentrated powder, 5 parts by weight of black-bone chicken peptide, 9 parts by weight of rehmannia root powder, 8 parts by weight of cistanche deserticola powder, and 1 part by weight of lemon concentrated powder.

[0049] The total weight of the composition in the example is 100 g, and its preparation method is the same as that of Example 1.

[0050] Example 4

[0051] This example provides a composition for improving premature ovarian failure, including 12 parts by weight of osmanthus flower pollen, 10 parts by weight of flaxseed concentrated powder, 3 parts by weight of black-bone chicken peptide, 15 parts by weight of rehmannia root powder, 4 parts by weight of cistanche deserticola powder, and 4 parts by weight of lemon concentrated powder.

[0052] The total weight of the composition in the example is 100 g, and its preparation method is the same as that of Example 1.

[0053] Example 5

[0054] This example provides a composition for improving premature ovarian failure, including 15 parts by weight of osmanthus flower pollen, 12 parts by weight of flaxseed concentrated powder, 8 parts by weight of black-bone chicken peptide, 20 parts by weight of rehmannia root powder, 2 parts by weight of cistanche deserticola powder, and 2 parts by weight of lemon concentrated powder.

[0055] The total weight of the composition in the example is 100 g, and its preparation method is the same as that of Example 1.

[0056] Comparative Example 1

[0057] This comparative example provides a composition for improving premature ovarian failure. The difference from Example 1 is that it does not include osmanthus flower pollen, that is, it includes 18 parts by weight of flaxseed concentrate powder, 4 parts by weight of black-bone chicken peptide, 13 parts by weight of rehmannia glutinosa powder, 6 parts by weight of cistanche deserticola powder, and 3 parts by weight of lemon concentrate powder.

[0058] The total weight of the composition in the comparative example is 100 g, and its preparation method is the same as that of Example 1.

[0059] Comparative Example 2

[0060] This comparative example provides a composition for improving premature ovarian failure. The difference from Example 1 is that it does not include flaxseed concentrate powder, that is, it includes 18 parts by weight of osmanthus flower pollen, 4 parts by weight of black-bone chicken peptide, 13 parts by weight of rehmannia glutinosa powder, 6 parts by weight of cistanche deserticola powder, and 3 parts by weight of lemon concentrate powder.

[0061] The total weight of the composition in the comparative example is 100 g, and its preparation method is the same as that of Example 1.

[0062] Comparative Example 3

[0063] This comparative example provides a composition for improving premature ovarian failure. The difference from Example 1 is that it does not include black-bone chicken peptide, that is, it includes 10 parts by weight of osmanthus flower pollen, 8 parts by weight of flaxseed concentrate powder, 13 parts by weight of rehmannia glutinosa powder, 6 parts by weight of cistanche deserticola powder, and 3 parts by weight of lemon concentrate powder.

[0064] The total weight of the composition in the comparative example is 100 g, and its preparation method is the same as that of Example 1.

[0065] Comparative Example 4

[0066] This comparative example provides a composition for improving premature ovarian failure. The difference from Example 1 is that it does not include rehmannia glutinosa powder, that is, it includes 10 parts by weight of osmanthus flower pollen, 8 parts by weight of flaxseed concentrate powder, 4 parts by weight of black-bone chicken peptide, 6 parts by weight of cistanche deserticola powder, and 3 parts by weight of lemon concentrate powder.

[0067] The total weight of the composition in the comparative example is 100 g, and its preparation method is the same as that of Example 1.

[0068] Comparative Example 5

[0069] This comparative example provides a composition for improving premature ovarian failure. The difference from Example 1 is that it does not include cistanche powder, that is, it includes 10 parts by weight of osmanthus powder, 8 parts by weight of flaxseed concentrate powder, 4 parts by weight of black-bone chicken peptide, 13 parts by weight of rehmannia powder, and 3 parts by weight of lemon concentrate powder.

[0070] The total weight of the comparative example composition is 100 g, and its preparation method is the same as that of Example 1.

[0071] Comparative Example 6

[0072] This comparative example provides a composition for improving premature ovarian failure. The difference from Example 1 is that it does not include lemon concentrate powder, that is, it includes 10 parts by weight of osmanthus powder, 8 parts by weight of flaxseed concentrate powder, 4 parts by weight of black-bone chicken peptide, 13 parts by weight of rehmannia powder, and 6 parts by weight of cistanche powder.

[0073] The total weight of the comparative example composition is 100 g, and its preparation method is the same as that of Example 1.

[0074] Comparative Example 7

[0075] This comparative example provides a composition for improving premature ovarian failure. The difference from Example 1 is that the ratio of black-bone chicken peptide to lemon concentrate powder is different. Specifically, it includes 10 parts by weight of osmanthus powder, 8 parts by weight of flaxseed concentrate powder, 1 part by weight of black-bone chicken peptide, 13 parts by weight of rehmannia powder, 6 parts by weight of cistanche powder, and 6 parts by weight of lemon concentrate powder.

[0076] The total weight of the comparative example composition is 100 g, and its preparation method is the same as that of Example 1.

[0077] Comparative Example 8

[0078] This comparative example provides a composition for improving premature ovarian failure. The difference from Example 1 is that the ratio of osmanthus and flaxseed concentrate powder is different. Specifically, it includes 3 parts by weight of osmanthus powder, 15 parts by weight of flaxseed concentrate powder, 4 parts by weight of black-bone chicken peptide, 13 parts by weight of rehmannia powder, 6 parts by weight of cistanche powder, and 3 parts by weight of lemon concentrate powder.

[0079] The total weight of the comparative example composition is 100 g, and its preparation method is the same as that of Example 1.

[0080] Experimental Example 1

[0081] The cyclophosphamide injection was purchased from Jiangsu Shengdi Pharmaceutical Co., Ltd.; the kits for estradiol (E2), luteinizing hormone (LH), and follicle-stimulating hormone (FSH) were all purchased from Wuhan Elite Biotech Co., Ltd.

[0082] To verify that the composition of the present invention has the effect of improving premature ovarian failure, the following animal experiments are described:

[0083] Animals: SD rats (female, 7 - 8 weeks old, body weight 170 - 190 g)

[0084] Model establishment: The rats were placed in an animal laboratory with a breeding temperature of 24 ± 2°C, a relative humidity of 50% - 60%, and a 12 - hour light - dark cycle, and were allowed to eat and drink freely. After 7 days of adaptive feeding, the rats were divided into a normal group (10 rats) and a model - making group (140 rats). The model - making group was prepared with a premature ovarian failure rat model by intraperitoneal injection of cyclophosphamide. The first dose of 50 mg / kg was injected for 1 day, and then the dose of 8 mg / kg was continuously injected for 14 days, for a total of 15 days. The rats in the normal group were injected with an equal volume of physiological saline.

[0085] Grouping: The successfully modeled rats were randomly divided into 14 groups, namely the model group, Examples 1 - 5, and Comparative Examples 1 - 8, with 10 rats in each group; the normal group and the model group were gavaged with ordinary feed and an equal amount of physiological saline, and Examples 1 - 5 and Comparative Examples 1 - 8 were gavaged with ordinary feed and the corresponding compositions; the rats were gavaged at the same time every day and continuously gavaged with the drug for 30 days.

[0086] The administration plan was to perform gavage once a day at a fixed time. According to the equivalent dose calculation method by body surface area ratio, when the human daily dose is 10 g, the gavage dose for rats was calculated to be 0.9 g / kg, and the rats were gavaged according to this dose.

[0087] 1.1 Determination of rat body weight change and ovarian index

[0088] After the last administration, the rats were fasted for 12 h, anesthetized by intraperitoneal injection of sodium pentobarbital, the abdominal cavity of the rats was opened, abdominal aortic blood was taken, left to stand at room temperature for 3 h, centrifuged at 3000 rpm in a low - temperature freezing centrifuge for 25 min, the serum was separated and aliquoted, and then stored in a - 80°C refrigerator for hormone analysis. The ovarian tissue was taken out, the fat was removed and weighed, and the ovarian index was calculated. The calculation formula of the ovarian index: Ovarian index (%) = (weight of a single ovary (g) / body weight of the rat (g)) × 100%. The experimental results are shown in Table 1 below.

[0089] Table 1 Determination results of body weight change and ovarian index of rats in each group

[0090]

[0091] Note: In the same column of the table, those with the same marked letter are not significantly different, and those with different marked letters in the same column are significantly different (P < 0.05).

[0092] Result analysis:

[0093] Compared with the normal group, the body weight, wet weight of the ovary and ovarian index of the rats in the model group decreased significantly, indicating that the rat premature ovarian failure model induced by cyclophosphamide was successfully established. Compared with the model group in Examples 1-5, the body weight, wet weight of the ovary and ovarian index of the rats increased significantly, indicating that the composition prepared by the present invention has the effect of improving premature ovarian failure.

[0094] The differences between Comparative Examples 1-6 and Example 1 were that one of the raw materials of osmanthus flower pollen, black-bone chicken peptide, rehmannia powder, cistanche powder or lemon concentrate powder was missing. From the results, it can be seen that the body weight, wet weight of the ovary and ovarian index of the rats in Comparative Examples 1-6 decreased significantly, indicating that the combination of raw materials selected by the present invention can cooperate synergistically to achieve a better effect of improving premature ovarian failure.

[0095] The difference between Comparative Example 7 and Example 1 was that the ratio of black-bone chicken peptide and lemon concentrate powder was different, and the difference between Comparative Example 8 and Example 1 was that the ratio of osmanthus flower pollen and flaxseed concentrate powder was different. From the results, it can be seen that the body weight, wet weight of the ovary and ovarian index of the rats in Comparative Examples 7-8 decreased significantly, indicating that changing the ratio of raw materials will also affect the effect of improving premature ovarian failure, and the composition provided by the present invention can better improve premature ovarian failure.

[0096] 1.2 Determination of biochemical indexes of rats

[0097] An enzyme-linked immunosorbent assay (Elisa) kit was used to measure estradiol (E2), luteinizing hormone (LH), and follicle-stimulating hormone (FSH) in the serum, and all experimental operations were carried out according to the reagent instructions. The experimental results are shown in Table 2 below.

[0098] Table 2 Determination results of biochemical indexes of rats in each group

[0099]

[0100] Note: In the same column of the table, those with the same marked letter are not significantly different, and those with different marked letters in the same column are significantly different (P<0.05).

[0101] Result analysis:

[0102] FSH and E2 are important indicators of ovarian function, which are secreted by the adenohypophysis and ovary respectively, and regulate ovarian follicle development and oogenesis. The process of ovarian aging is accompanied by a significant decrease in estrogen and an increase in FSH. LH mainly acts on follicle development, ovulation process and corpus luteum formation.

[0103] Compared with the normal group, the content of E2 in the rats of the model group decreased significantly, while the contents of LH and FSH increased significantly, indicating that the rat ovarian premature aging model induced by cyclophosphamide was successfully established. Compared with the model group in Examples 1-5, the content of E2 in the rats increased significantly, while the contents of LH and FSH decreased significantly, indicating that the composition prepared by the present invention has the effect of improving ovarian premature aging.

[0104] Compared with Example 1, in Comparative Examples 1-6, the content of E2 in the rats decreased to varying degrees, while the contents of LH and FSH increased to varying degrees, indicating that the synergistic effect of the types of raw materials selected in the present invention can better improve the phenomenon of ovarian premature aging.

[0105] Compared with Example 1, in Comparative Examples 7-8, the content of E2 in the rats decreased significantly, while the contents of LH and FSH increased significantly, indicating that the proportion of raw materials also affects the efficacy of improving ovarian premature aging. Therefore, the proportion of raw materials in the present invention is the optimal choice and can better achieve the efficacy of improving ovarian premature aging.

[0106] Finally, it should be noted that the above content is only used to illustrate the technical solution of the present invention, rather than a limitation on the protection scope of the present invention. Any simple modification or equivalent replacement of the technical solution of the present invention by those of ordinary skill in the art shall not depart from the essence and scope of the technical solution of the present invention.

Claims

1. A composition for improving premature ovarian failure, characterized in that, By weight, it includes 5 - 15 parts of osmanthus flower pollen, 4 - 12 parts of flaxseed concentrated powder, 2 - 8 parts of black-bone chicken peptide, 4 - 20 parts of rehmannia root powder, 2 - 10 parts of cistanche deserticola powder, and 1 - 5 parts of lemon concentrated powder.

2. The composition for improving premature ovarian failure according to claim 1, wherein By weight, it includes 8 - 12 parts of osmanthus flower pollen, 7 - 10 parts of flaxseed concentrated powder, 3 - 5 parts of black-bone chicken peptide, 9 - 15 parts of rehmannia root powder, 4 - 8 parts of cistanche deserticola powder, and 2 - 4 parts of lemon concentrated powder.

3. The composition for improving premature ovarian failure according to claim 1, wherein The weight ratio of the osmanthus flower pollen to the flaxseed concentrated powder is (1 - 1.5):

1.

4. The composition for improving premature ovarian failure according to claim 1, wherein, The weight ratio of the total weight of the osmanthus flower pollen and the flaxseed concentrated powder to the lemon concentrated powder is (1.5 - 15):1; The weight ratio of the total weight of the osmanthus flower pollen and the flaxseed concentrated powder to the black-bone chicken peptide is (3 - 8):1; The weight ratio of the total weight of the osmanthus flower pollen and the flaxseed concentrated powder to the rehmannia root powder is (1 - 3):

1.

5. The composition for improving premature ovarian failure according to claim 1, wherein By weight, it includes 10 parts of osmanthus flower pollen, 8 parts of flaxseed concentrated powder, 4 parts of black-bone chicken peptide, 13 parts of rehmannia root powder, 6 parts of cistanche deserticola powder, and 3 parts of lemon concentrated powder.

6. The composition for improving premature ovarian failure according to claim 1, wherein The content of acteoside in the osmanthus flower pollen is not less than 12%.

7. The composition for improving premature ovarian failure according to claim 1, characterized in that, The content of lignans in the flaxseed concentrated powder is not less than 40%.

8. A method for preparing the composition for improving premature ovarian failure according to any one of claims 1-7, characterized in that, The steps are: weighing osmanthus flower pollen, flaxseed concentrated powder, black-bone chicken peptide, rehmannia root powder, cistanche deserticola powder, and lemon concentrated powder, mixing evenly and sterilizing by ultraviolet light to obtain the composition.

9. The preparation method according to claim 8, characterized in that, The mixing time is 20 - 40 min.

10. Use of the composition according to any one of claims 1 - 7 and the composition obtained by the preparation method according to any one of claims 8 - 9 in the preparation of products for improving premature ovarian failure.

Images